Press Releases

WASHINGTON, Feb. 12 – Senators Bernie Sanders (I-Vt.) and Patrick Leahy (D-Vt.) announced that the Senate passed the Natural Resources Management Act on Tuesday evening by a 92-8 vote. This comprehensive public lands bill includes two provisions of particular importance to Vermonters.  The bill permanently reauthorizes the Land and Water Conservation Fund (LWCF). Congress created the LWCF in 1965 to

WASHINGTON, Feb. 6 – Sen. Bernie Sanders (I-Vt.) demanded answers Wednesday from the Department of Health and Human Services and the U.S. Centers for Medicare and Medicaid Services about the cost to taxpayers of Catalyst Pharmaceuticals’ drug Firdapse. Catalyst recently announced an annual list price of $375,000 for the medication, which patients previously received for free from Jacobus Pharmaceutical. “I am writing to

Let me thank all of you for joining me tonight for a brief response to President Trump’s State of the Union address. And let me thank Stacey Abrams for her extremely effective response. Now, we all know why she would have been a wonderful Governor of Georgia. I know that this will probably not shock you, but not everything President

WASHINGTON, Feb. 4 – Sen. Bernie Sanders (I-Vt.) issued the following statement Monday regarding Walmart’s announcement that they will allow employees to earn up to 48 hours of paid time off: “Walmart’s decision to provide 48 hours of paid sick leave to some of its employees is a small step forward, but not nearly good enough. Walmart, which is owned by

BURLINGTON, Vt., Feb. 4 – U.S. Sen. Bernie Sanders (I-Vt.) on Monday announced the winners of his ninth annual State of the Union essay contest, which gives Vermont high school students an opportunity to describe which issues they would prioritize if they were president.  This year, 590 students from 50 Vermont high schools submitted 250-500 word essays on issues that

WASHINGTON, Feb. 4 – In a letter sent Monday to the CEO of Catalyst Pharmaceuticals, Sen. Bernie Sanders (I-Vt.) demanded the company explain its decision to set the price of Firdapse, a drug used to treat a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS), at $375,000 per year.   For two decades, patients have received the same drug – known